3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Carcinoma, Merkel Cell
8
Urinary Bladder Neoplasms
7
Pancreatic Neoplasms
6
Neoplasm Metastasis
6
Triple Negative Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Ovarian Neoplasms
4
Neoplasms
4
Stomach Neoplasms
3
Prostatic Neoplasms
3
Melanoma
3
Leukemia, Myeloid, Acute
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Sarcoma
2
Head and Neck Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Squamous Cell
2
Carcinoma, Ovarian Epithelial
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Ureteral Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Recurrence
1
Ovarian Diseases
1
Non-Muscle Invasive Bladder Neoplasms
1
Neuroendocrine Tumors
1
Interventions
Peripheral Blood Stem Cell Transplantation
11
Mycophenolic Acid
8
Cyclosporine
8
fludarabine phosphate
7
Imatinib Mesylate
6
Busulfan
5
Tacrolimus
4
Radiotherapy
4
Methotrexate
4
Cyclophosphamide
4
nilotinib
3
bosutinib
3
Whole-Body Irradiation
3
Cord Blood Stem Cell Transplantation
3
Antilymphocyte Serum
3
Melphalan
2
Filgrastim
2
Dasatinib
2
Cytarabine
2
Alemtuzumab
2
sargramostim
1
ruxolitinib
1
ponatinib
1
montanide ISA 51
1
liposomal doxorubicin
1
ethanolamine oleate
1
avelumab
1
atezolizumab
1
aldesleukin
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Leukemia, Myeloid, Chronic-Phase
×
avelumab
×
Clear all
NCT02767063
2020-08-07
ACTIW
Versailles Hospital
Phase 1/2
Unknown
100 enrolled